Back to search results

Intraperitoneal Paclitaxel with NALIRIFOX for Pancreatic Cancer

This study is looking at a new way to treat pancreatic cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis). It combines two chemotherapy treatments: paclitaxel, given directly into your abdomen, and NALIRIFOX, given into a vein. NALIRIFOX is a combination of drugs (liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin) that was recently approved for metastatic pancreatic cancer. Researchers want to see if this combination is safe and how well it works for people with this type of pancreatic cancer. They will be looking at any side effects you might experience. You can join if you are 18 or older and have pancreatic cancer that has spread only to your peritoneum, confirmed by a biopsy.

Study design
This is an interventional study planning to enroll 10 participants. The phase of the study is not specified.
What's involved
You will need to sign a consent form and be willing to follow all study procedures for the duration of the study.
Compensation
Not stated in the trial record.
Follow-up
Your adverse events will be monitored from enrollment through 30 days after your last dose of treatment, which is approximately 7 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07030283

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of Colorado, Denver
~10 participants
Updated 2026-02-02 on ClinicalTrials.gov
What's tested:PaclitaxelNALIRIFOX

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse event rate
Measured over From enrollment through 30 days after last dose of treatment administered (approximately 7 months)

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07030283

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Colorado Cancer Center

    Aurora, Coloradostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Alexis Leal, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

Puja Gupta Poddar
[email protected]
720-278-0236
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute neutrophil count (ANC) \>/= 1,500 per cubic millimeter without the use of hematopoietic growth factors within 14 days prior to screening
Platelet count \>/= 75,000 per cubic millimeter
Hemoglobin \> 9 g/dL 10. Adequate hepatic function as evidenced by:
Serum total bilirubin ≤ 1.5x ULN (biliary drainage is allowed for biliary obstruction), and
AST and ALT ≤ 3 x ULN 11. Adequate renal function as evidenced by serum creatinine \<1.5 x ULN

What this trial measures

  • Adverse event rateFrom enrollment through 30 days after last dose of treatment administered (approximately 7 months)